PTCT News
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PR NewswireWARREN, N.J., Oct. 15, 2026WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...
PR Newswire
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PR NewswireWARREN, N.J., Oct. 15, 2026WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...
PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireWARREN, N.J., Sept. 25, 2026 WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced...
PR Newswire
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy PTC Completes Acquisition of ST-920 Fabry Disease Gene TherapyPR NewswireWARREN, N.J., Sept. 21, 2026 Completion of BLA submission expected in Q4 2026 WARREN, N.J., Sept. 21, 2026 /PRNewswire/ --PTC Therapeutics, Inc., (NASDAQ: PTCT...
PR Newswire
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics to Participate in Upcoming Investor Conferences PR Newswire WARREN, N.J., Aug. 27, 2026 WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak...
PR Newswire
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Zacks
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
Zacks
PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits...
PR Newswire
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo's ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.read more...
Benzinga
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PR Newswire WARREN, N.J., Aug. 12, 2026 Planned acquisition leverages existing regulatory and commercial...
PR Newswire